Drug repurposing: progress, challenges and recommendations (Q57471980)

2

0 references

Andrew J Doig

object named as

Andrew Doig

7

0 references

David Cavalla

13

object named as

David Cavalla

0 references

author name string

Sudeep Pushpakom

1

0 references

Patrick A Eyers

3

0 references

K Jane Escott

4

0 references

Shirley Hopper

5

0 references

Andrew Wells

6

0 references

Tim Guilliams

8

0 references

Joanna Latimer

9

0 references

Christine McNamee

10

0 references

Alan Norris

11

0 references

Munir Pirmohamed

14

0 references

Patrick A. Eyers

3

0 references

K. Jane Escott

Nature Reviews Drug Discovery

4

0 references

language of work or name

English

0 references

publication date

12 October 2018

0 references

published in

0 references

exact match

https://scigraph.springernature.com/pub.10.1038/nrd.2018.168

0 references

cites work

Drug repositioning: identifying and developing new uses for existing drugs

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Diagnosing the decline in pharmaceutical R&D efficiency

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

The productivity crisis in pharmaceutical R&D.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

An analysis of the attrition of drug candidates from four major pharmaceutical companies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Overcoming the legal and regulatory barriers to drug repurposing

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Can you teach old drugs new tricks?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Antitumor activity of thalidomide in refractory multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Market watch: Top drugs and companies by sales in 2017

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Computational drug repositioning: from data to therapeutics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Predicting new molecular targets for known drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Exploiting drug-disease relationships for computational drug repositioning

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Transcriptional data: a new gateway to drug repositioning?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Discovery and preclinical validation of drug indications using compendia of public gene expression data

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Drugs that reverse disease transcriptomic signatures are more effective in a mouse model of dyslipidemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Repositioning of a cyclin-dependent kinase inhibitor GW8510 as a ribonucleotide reductase M2 inhibitor to treat human colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Identify potential drugs for cardiovascular diseases caused by stress-induced genes in vascular smooth muscle cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

mRNA expression signatures of human skeletal muscle atrophy identify a natural compound that increases muscle mass

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Connectivity mapping (ssCMap) to predict A20-inducing drugs and their antiinflammatory action in cystic fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Genetic regulation of gene expression in the epileptic human hippocampus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Drug Signature-based Finding of Additional Clinical Use of LC28-0126 for Neutrophilic Bronchial Asthma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Systematic evaluation of drug-disease relationships to identify leads for novel drug uses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Identification of small molecules enhancing autophagic function from drug network analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Unravelling druggable signalling networks that control F508del-CFTR proteostasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

A Semi-Supervised Approach for Refining Transcriptional Signatures of Drug Response and Repositioning Predictions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Extraction and analysis of signatures from the Gene Expression Omnibus by the crowd.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

DvD: An R/Cytoscape pipeline for drug repurposing using public repositories of gene expression data.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

sscMap: an extensible Java application for connecting small-molecule drugs using gene-expression signatures

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

31 March 2020

Systems chemical biology

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Drug target identification using side-effect similarity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Systematic drug repositioning based on clinical side-effects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Docking and scoring in virtual screening for drug discovery: methods and applications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Predicting new indications for approved drugs using a proteochemometric method

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Structures of G protein-coupled receptors reveal new opportunities for drug discovery.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Reverse docking: a powerful tool for drug repositioning and drug rescue

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Reverse Screening Methods to Search for the Protein Targets of Chemopreventive Compounds.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

A critical assessment of docking programs and scoring functions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Software for molecular docking: a review.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Use of genome-wide association studies for drug repositioning

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Novel therapeutics for coronary artery disease from genome-wide association study data.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Rational drug repositioning by medical genetics.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

New human gene tally reignites debate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Identification of common biological pathways and drug targets across multiple respiratory viruses based on human host gene expression analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Pathway and network-based strategies to translate genetic discoveries into effective therapies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Network based elucidation of drug response: from modulators to targets

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Understanding multicellular function and disease with human tissue-specific networks

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Retrospective clinical analysis for drug rescue: for new indications or stratified patient groups.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Mining electronic health records: towards better research applications and clinical care

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Repurpose terbutaline sulfate for amyotrophic lateral sclerosis using electronic medical records

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

A Biomarker Harvest from One Thousand Cancer Cell Lines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

31 March 2020

Cell lines battle cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

A landscape of pharmacogenomic interactions in cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Extracting research-quality phenotypes from electronic health records to support precision medicine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

China Kadoorie Biobank of 0.5 million people: survey methods, baseline characteristics and long-term follow-up

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

A phenome-wide association study of a lipoprotein-associated phospholipase A2 loss-of-function variant in 90 000 Chinese adults

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Big data: The power of petabytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

The 100,000 Genomes Project

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

A new initiative on precision medicine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

China embraces precision medicine on a massive scale

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Targeted therapy in patients with PIK3CA-related overgrowth syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Accelerated clinical discovery using self-reported patient data collected online and a patient-matching algorithm

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

The use of cellular thermal shift assay (CETSA) to study Crizotinib resistance in ALK-expressing human cancers.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

NQO2 is a reactive oxygen species generating off-target for acetaminophen.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Use of a drug-resistant mutant of stress-activated protein kinase 2a/p38 to validate the in vivo specificity of SB 203580.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Protein kinases--the major drug targets of the twenty-first century?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Choose and Use Your Chemical Probe Wisely to Explore Cancer Biology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Paradoxical activation of Raf by a novel Raf inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Chemical Proteomics Reveals Ferrochelatase as a Common Off-target of Kinase Inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Crizotinib inhibits NF2-associated schwannoma through inhibition of focal adhesion kinase 1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Drug-resistant aurora A mutants for cellular target validation of the small molecule kinase inhibitors MLN8054 and MLN8237

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

The hVps34-SGK3 pathway alleviates sustained PI3K/Akt inhibition by stimulating mTORC1 and tumour growth

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Comprehensive analysis of kinase inhibitor selectivity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

A quantitative analysis of kinase inhibitor selectivity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Non-kinase targets of protein kinase inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Opportunities and challenges in phenotypic drug discovery: an industry perspective

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

High-throughput cell-based screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Larval zebrafish model for FDA-approved drug repositioning for tobacco dependence treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Drug reformulations and repositioning in the pharmaceutical industry and their impact on market access: regulatory implications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Pioneering government-sponsored drug repositioning collaborations: progress and learning.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

NCATS launches drug repurposing program

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Seeding collaborations to advance kinase science with the GSK Published Kinase Inhibitor Set (PKIS)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

A public-private partnership to unlock the untargeted kinome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Discovery of Novel Small Molecules that Activate Satellite Cell Proliferation and Enhance Repair of Damaged Muscle.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Comprehensive characterization of the Published Kinase Inhibitor Set

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Database identifies FDA-approved drugs with potential to be repurposed for treatment of orphan diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Topiramate use does not reduce flares of inflammatory bowel disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

GABA and GABA receptors in the gastrointestinal tract: from motility to inflammation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Identification of small molecules enhancing autophagic function from drug network analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Role of autophagy in the pathogenesis of amyotrophic lateral sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Fasudil, a rho kinase inhibitor, limits motor neuron loss in experimental models of amyotrophic lateral sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Rho Kinase Inhibition with Fasudil in the SOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis-Symptomatic Treatment Potential after Disease Onset

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Rho kinase inhibition modulates microglia activation and improves survival in a model of amyotrophic lateral sclerosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Integrative methods for analyzing big data in precision medicine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

IBM Watson: How Cognitive Computing Can Be Applied to Big Data Challenges in Life Sciences Research

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Methods of integrating data to uncover genotype-phenotype interactions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

A network integration approach for drug-target interaction prediction and computational drug repositioning from heterogeneous information.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Drug repositioning: a machine-learning approach through data integration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Fyn inhibition rescues established memory and synapse loss in Alzheimer mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Effects of Src-kinase inhibition in cancer-induced bone pain.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

SRC kinase is a novel therapeutic target in lymphangioleiomyomatosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Atypical antipsychotics and a Src kinase inhibitor (PP1) prevent cortical injury produced by the psychomimetic, noncompetitive NMDA receptor antagonist MK-801.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Neurokinin 3 receptor antagonism - the magic bullet for hot flushes?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Neurokinin B administration induces hot flushes in women.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Role for kisspeptin/neurokinin B/dynorphin (KNDy) neurons in cutaneous vasodilatation and the estrogen modulation of body temperature

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Hypertrophy and Increased Gene Expression of Neurons Containing Neurokinin-B and Substance-P Messenger Ribonucleic Acids in the Hypothalami of Postmenopausal Women*

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Activation of neurokinin 3 receptors in the median preoptic nucleus decreases core temperature in the rat.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Association of genetic variation in the tachykinin receptor 3 locus with hot flashes and night sweats in the Women's Health Initiative Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Is there still a future for neurokinin 3 receptor antagonists as potential drugs for the treatment of psychiatric diseases?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Deal watch: Neurokinin 3 receptor antagonist revival heats up with Astellas acquisition.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Remission of inflammatory arthropathy in association with anti-CD20 therapy for non-Hodgkin's lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Rituximab: how approval history is reflected by a corresponding patent filing strategy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

The rise and fall of Dimebon

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Assessing the Efficacy and Safety of an 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017) in the Idiopathic Intracranial Hypertension Drug Trial, IIH:DT: Clinical Methods and Design for a Phase II Randomized Controlled Trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.168

Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases.

31 March 2020

1 reference

12 December 2020

Cellular targets of gefitinib

1 reference

12 December 2020

Talnetant GlaxoSmithKline.

1 reference

12 December 2020

Discovery of drug mode of action and drug repositioning from transcriptional responses

1 reference

12 December 2020

Phase II study of saracatinib (AZD0530) for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).

1 reference

12 December 2020

Rapid antimicrobial susceptibility test for identification of new therapeutics and drug combinations against multidrug-resistant bacteria

1 reference

12 December 2020

Identifying new antiepileptic drugs through genomics-based drug repurposing

1 reference

12 December 2020